Change in revenue reporting
As announced in connection with the publication of the 2006 full-year results, Novozymes will change its revenue reporting in 2007.
As announced in connection with the publication of the 2006 full-year results, Novozymes will change its revenue reporting in 2007. With the increasing activities within solutions for the biopharmaceutical industry, it has been decided to report these activities as a separate business area, creating more revenue transparency.
The new business area is named Biopharmaceutical Ingredients, and will comprise the activities related to Novozymes Delta, Novozymes GroPep, Novozymes Biopharma and also the research project within recombinant human serum albumin (rHSA).
Historically these revenue streams have been reported as other technical enzymes. Table 1 below discloses a breakdown of 2005 and 2006 quarterly sales of other technical enzymes in the old reporting and the new reporting split between technical enzymes and biopharmaceutical ingredients.
|Total technical enzymes||374||425||442||479||1,720||476||490||520||625||2,111|